ICU Medical

ICU Medical, Inc. is a medical technology company headquartered in San Clemente, California. Its products are intended to support the delivery of intravenous therapy, reduce risks associated with vascular access, protect healthcare workers from infectious and hazardous-drug exposure, and provide monitoring capabilities for critically ill patients. The company operates across several connected areas of hospital care rather than concentrating on a single device category. Its portfolio includes intravenous therapy products, infusion pumps, needle-free vascular access devices, custom infusion sets, closed systems for handling hazardous drugs, sensor catheters, needle-free closed blood-sampling systems, and hemodynamic monitoring systems. The company was founded in 1984 by George "Doc" Lopez, MD. Its early development was associated with the ClickLock product, which was designed to improve the security of intravenous lines. This initial emphasis on safer and more reliable IV access became a continuing theme in ICU Medical's product strategy. Over time, the company expanded from line-security devices into a broader medical-device business serving infusion, oncology, vascular access, and critical-care workflows. A significant product-area expansion occurred in 2006, when ICU Medical introduced its first oncology products. The ChemoClave system was developed as a closed system transfer device for the preparation and administration of hazardous drugs, including medicines used in cancer treatment. By creating a contained connection and transfer environment, the system was intended to reduce occupational exposure for pharmacists and nurses who handle these drugs. ICU Medical subsequently broadened its oncology offering with the Diana Hazardous Drug Compounding System, introduced in 2012. Diana is a user-controlled automated compounding system intended to help reduce exposure to hazardous drugs and accidental needlestick injuries while limiting contamination risks during patient preparation. The company's scale and product breadth also increased through acquisitions and business arrangements. In 2009, ICU Medical acquired the former Abbott Laboratories Critical Care business from Hospira, following a four-year arrangement under which ICU Medical had manufactured Hospira's critical-care product line. In February 2017, ICU Medical acquired Hospira's Infusion Systems business from Pfizer. These transactions connected ICU Medical's established vascular-access and safety portfolio with infusion-system and critical-care capabilities. In 2015, ICU Medical acquired Excelsior Medical Corporation, a manufacturer of products designed to disinfect and protect access points into the bloodstream. The acquired portfolio included SwabCap and SwabFlush products, as well as pre-filled saline and heparin flush syringes. ICU Medical later sold the operating assets associated with SwabFlush and the pre-filled syringe businesses to Medline Industries for $27 million, while retaining the other acquired activities described in the source material. The Excelsior transaction was reported at a total purchase price of $59.5 million. Within critical care, ICU Medical's offerings include hemodynamic monitoring products, blood-conservation solutions, oximetry catheter technologies, critical-care catheters, and hemodynamic transducer kits. Its sensor-catheter portfolio is described as latex-free, an attribute intended to reduce the risk of allergic reactions. The Neutron device addresses catheter occlusion associated with external influences such as luer connection and disconnection or changes in patient vascular pressure. The company has stated that Neutron may reduce catheter occlusion incidence by approximately 50% in clinical use, although the precise study context is not provided in the available reference material. ICU Medical has also received corporate recognition. In 2014, Forbes named it among America's 100 Most Trustworthy Companies. Overall, the brand is positioned around safety-oriented hospital technology: maintaining reliable IV access, reducing contamination and exposure risks, supporting safe hazardous-drug handling, and helping clinicians monitor and manage critically ill patients. The supplied sources do not provide current executive information, revenue, ownership details, stock information, or a definitive list of countries in which the company operates.

ICU Medical was established in 1984 by George "Doc" Lopez, MD. The company's early work focused on intravenous-line security, including the ClickLock product, which was designed to help secure IV lines. This beginning gave the company a continuing focus on safer vascular access and the reduction of avoidable risks during infusion therapy. The business later developed into a broader medical-technology company serving infusion, oncology, vascular access, and critical-care settings. In 2006, ICU Medical entered the oncology market with its first oncology products. Its ChemoClave closed system transfer device was designed to help pharmacists and nurses mix and administer hazardous cancer drugs while reducing exposure to those substances. The company expanded this safety-oriented oncology strategy in 2012 with the Diana Hazardous Drug Compounding System, a user-controlled automated system intended to reduce hazardous-drug exposure and accidental needlestick risks during compounding. ICU Medical expanded its critical-care presence through a business relationship and subsequent acquisition involving Hospira. After manufacturing Hospira's critical-care product line for four years, ICU Medical acquired the former Abbott Laboratories Critical Care business from Hospira in 2009. The transaction added critical-care technologies to the company's existing infusion and vascular-access activities. In 2017, ICU Medical acquired Hospira's Infusion Systems business from Pfizer, further increasing its participation in infusion-system markets. Another important expansion came in 2015, when ICU Medical acquired Excelsior Medical Corporation. Excelsior made devices used to disinfect and protect bloodstream-access points. Its products included SwabCap and SwabFlush, along with pre-filled saline and heparin flush syringes. ICU Medical subsequently sold the SwabFlush and pre-filled syringe operating assets to Medline Industries for $27 million. The reported total purchase price for Excelsior was $59.5 million. The resulting portfolio spans infusion pumps, IV sets, needle-free connectors, closed vascular-access systems, hazardous-drug transfer and compounding equipment, catheter products, blood-sampling systems, and hemodynamic monitoring technologies. The Neutron device was developed to address catheter occlusion associated with line manipulation and changes in patient vascular pressure. ICU Medical's critical-care offerings also include blood-conservation products, oximetry catheter technology, latex-free sensor catheters, and hemodynamic transducer kits. The company received external recognition in 2014, when Forbes included it among America's 100 Most Trustworthy Companies. The available reference material identifies ICU Medical as an active company headquartered in San Clemente, California, but does not supply current ownership, executive, financial, website, or geographic operating-market information.

• 2017

  Hospira Infusion Systems acquisition

  [1]ICU Medicalen.wikipedia.org

  ICU Medical acquired Hospira's Infusion Systems business from Pfizer.

• 2015

  Excelsior Medical acquisition

  [1]ICU Medicalen.wikipedia.org

  ICU Medical acquired Excelsior Medical, adding bloodstream-access disinfection, protection, and flushing products.

• 2014

  Named among America's 100 Most Trustworthy Companies

  [1]ICU Medicalen.wikipedia.org

  Forbes included ICU Medical in its list of America's 100 Most Trustworthy Companies.

• 2012

  Diana hazardous-drug compounding system introduced

  [1]ICU Medicalen.wikipedia.org

  The company introduced Diana, an automated system intended to help protect clinicians during hazardous-drug compounding and reduce accidental needlestick risks.

• 2009

  Acquisition of former Abbott Critical Care business

  [1]ICU Medicalen.wikipedia.org

  ICU Medical acquired the former Abbott Laboratories Critical Care business from Hospira after a four-year manufacturing arrangement.

• 2006

  Entry into oncology safety products

  [1]ICU Medicalen.wikipedia.org

  ICU Medical introduced its first oncology products, including the ChemoClave closed system transfer device for hazardous-drug handling.

• 1984

  Company founded

  [1]ICU Medicalen.wikipedia.org

  George "Doc" Lopez, MD founded ICU Medical, with early development centered on the ClickLock IV-line security product.

A hospital medical-technology brand centered on infusion safety, vascular access, hazardous-drug protection, and critical-care monitoring.

• Oncology safety · 2006

  ChemoClave

  ChemoClave is a closed system transfer device designed for the preparation and administration of hazardous drugs, including cancer medicines. Its contained transfer approach is intended to reduce occupational exposure for pharmacists and nurses who mix or administer these substances. The system reflects ICU Medical's broader emphasis on protecting healthcare workers while supporting controlled medication delivery.

• Oncology compounding · 2012

  Diana Hazardous Drug Compounding System

  Diana is a user-controlled automated system for compounding hazardous drugs. It is designed to help reduce clinician exposure, accidental needlestick injuries, and contamination risks during the preparation of medicines for patients. The system forms part of ICU Medical's oncology portfolio and extends the safety goals represented by its closed-system transfer products.

• Vascular access

  Neutron

  Neutron is a device intended to reduce catheter occlusion associated with external factors, including luer connection and disconnection and vascular-pressure changes caused by actions such as coughing, sneezing, crying, or vomiting. ICU Medical materials cited in the reference state that clinical use may reduce catheter occlusion incidence by approximately 50%, although the available material does not identify the underlying study.

• Vascular access disinfection

  SwabCap

  SwabCap is a disinfecting and protective access-cap product acquired through ICU Medical's purchase of Excelsior Medical. It is intended for use on access points into the bloodstream and supports infection-control practices around vascular access.

• Critical care

  Critical-care monitoring and catheter portfolio

  ICU Medical's critical-care portfolio includes hemodynamic monitoring products, blood-conservation solutions, oximetry catheter technology, sensor catheters, critical-care catheters, and hemodynamic transducer kits. The portfolio is intended to provide real-time physiological information and support management of oxygen delivery, circulation, and other aspects of care for critically ill patients.

• 2017

  Acquire Hospira Infusion Systems from PfizerM&A

  Background

  Hospira's Infusion Systems business represented an opportunity to expand ICU Medical's infusion-system capabilities.

  Action taken

  ICU Medical acquired the Hospira Infusion Systems business from Pfizer.

  Aftermath

  The acquisition strengthened the company's position in infusion systems and expanded the scope of its hospital-device portfolio.

  Source

• 2015

  Acquire Excelsior Medical CorporationM&A

  Background

  Excelsior Medical produced devices used to disinfect and protect bloodstream access, including SwabCap, SwabFlush, and pre-filled flush syringes.

  Action taken

  ICU Medical acquired Excelsior Medical for a reported total purchase price of $59.5 million.

  Aftermath

  ICU Medical added bloodstream-access protection products, then sold the SwabFlush and pre-filled syringe operating assets to Medline Industries for $27 million.

  Reported transaction purchase and divestiture values. (2015)

  Source

• 2009

  Acquire the former Abbott Laboratories Critical Care businessM&A

  Background

  ICU Medical had manufactured Hospira's critical-care product line for four years before acquiring the former Abbott Laboratories Critical Care business from Hospira.

  Action taken

  The company completed the acquisition and expanded its critical-care product activities.

  Aftermath

  The transaction broadened ICU Medical's portfolio beyond its original IV-line and vascular-access focus.

  Source

1. 1ICU Medicalen.wikipedia.org